Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
Stocks · News reference
Connect Biopharma shares are trading higher after the company announced preliminary topline data from its global Phase 2 study evaluating rademikibart. Results included Rademikibart reducing rate of treatment failure, rate of moderate to severe COPD exacerbations and reduced the rate of new emergency departments and hospital admissions.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Connect Biopharma reports positive Phase 2 results for rademikibart, showing an 81% reduction in COPD treatment failure and high safety.
BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5
Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold also climbed.